GLP-1 SEO is search engine optimisation for companies that offer GLP-1 medications and medical weight-management programmes: telehealth platforms, clinics and weight-management brands. It targets the commercial, comparison, cost, local and brand searches patients use to choose a provider, under YMYL scrutiny and the FDA, FTC and state attention this category receives, and it is built to reduce the share of patients a company has to buy through paid channels.
Who it is for
GLP-1 telehealth platforms competing nationally against pharmacies, media and each other. Medical weight-loss clinics competing locally on treatment and provider searches. Weight-management platforms where GLP-1 is one programme among several. Pharmacies and compounders where appropriate, and the growth teams that serve all of them. Each has a different rulebook and a different SERP; we do not assume they share either.
What the SERPs look like
On 8 September 2026 we pulled the Google US top ten for twelve patient-facing commercial queries. Clinics and telehealth brands held 48 of 120 positions, media 8, community sites 17; pharmacies and national platforms recur across queries (GoodRx on 9 of 12, Walgreens on 8, WeightWatchers on 7). Median authority 408 of 1,000; only 8 positions under 150. AI Overviews on 8 of 12. Head terms are a wall. Comparison, cost, eligibility, state and brand queries are the open field.
How it differs from ordinary healthcare SEO
- Enforcement is active and specific to website copy. FDA's 2026 letters cite equivalence claims about compounded drugs (which are not FDA-approved), language implying approval, and sourcing ambiguity on telehealth sites. Titles, treatment pages, comparisons and FAQs are in scope.
- The product universe moves. Compounding rules, shortage status and litigation changed what could be marketed at least three times in eighteen months.
- Patient acquisition economics dominate. CAC on paid is the operator's daily pain; SEO is judged on its share of new patients, not on traffic.
- Health data is a regulatory subject. Pixels and tracking on health sites drew FTC action in 2026; measurement has to be designed, not bolted on.
How the work runs
Commercial SERP map and near-win audit first. Then five fronts in parallel: money-page architecture (programme, treatment, comparison and cost pages written for a regulator as well as a reader), authority and link acquisition against a high-authority field, near-win optimisation including our proprietary engagement-signal process where a page qualifies, content and entity authority for People Also Ask and the answer engines, and a standing wording check with a dated rule store. How we work describes each part.
What it costs
Retainers are priced around your market and what needs building, quoted after the strategy call. Month to month.
What we are not
We are not clinicians, lawyers or regulatory consultants, and nothing here is directed at patients. We flag wording that deserves review, cite the source of the concern and escalate to your counsel. We do not certify compliance and we do not promise rankings.
Sources
- GLP-1SEO SERP sample, 12 patient-facing commercial queries, US desktop (2026-09-08) — https://glp-1seo.com/insights/who-owns-the-glp-1-telehealth-serps-2026/
- FDA: FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s (2026-03-03) — https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1-s
GLP-1SEO provides search-marketing services and publishes search-marketing analysis. We are not physicians, pharmacists, lawyers or regulatory consultants, and nothing on this site is medical, legal or regulatory advice, or advice to patients. Clients remain responsible for obtaining qualified advice about their products, claims, jurisdictions and operations.